Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study

Core Insights - Rademikibart demonstrated rapid and durable efficacy results across all key endpoints through 52 weeks, achieving near-maximal responses in approximately 90% of patients [1][2] - The safety profile of Rademikibart was comparable to placebo, with low rates of conjunctivitis, a common side effect associated with similar treatments [2][3] - The results were presented at the 2026 American Academy of Dermatology Annual Meeting, highlighting the potential of Rademikibart as a best-in-class treatment for atopic dermatitis [1][2] Study Results - The Phase 3 study was a double-blind, placebo-controlled trial involving 259 patients with moderate-to-severe atopic dermatitis, randomized to receive Rademikibart or placebo [3] - At Week 52, 96.6% of patients achieved a ≥75% reduction in the Eczema Area and Severity Index (EASI-75), 87.1% achieved a score of 0 or 1 on the Investigator's Global Assessment (IGA 0/1), and 85.3% achieved a ≥90% reduction in EASI (EASI-90) [3] - Rademikibart was well tolerated, with no significant drug-related safety issues observed in over 1,500 participants across various studies [3] Company Overview - Connect Biopharma is a clinical-stage biopharmaceutical company focused on transforming care for inflammatory diseases, particularly asthma and COPD [7] - The company is advancing Rademikibart, a next-generation monoclonal antibody targeting IL-4Rα, and is conducting global clinical studies for its efficacy in treating acute exacerbations of asthma and COPD [7] - Connect Biopharma has an exclusive licensing agreement with Simcere Pharmaceutical for Rademikibart in Greater China, with potential milestone payments up to approximately $110 million and tiered royalties on net sales [7]